Literature DB >> 10898709

In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria.

H M Wexler1, D Molitoris, S M Finegold.   

Abstract

The activity of MK-826 was compared to the activities of cefoxitin, ceftriaxone, imipenem, and meropenem against 363 gram-negative and gram-positive anaerobes by using NCCLS procedures. At least 98% of the strains were susceptible to the carbapenems. All strains of Clostridium perfringens, Fusobacterium nucleatum, Peptostreptococcus, and Sutterella wadsworthensis were susceptible to all agents tested.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10898709      PMCID： PMC90047          DOI： 10.1128/AAC.44.8.2222-2224.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

2.  In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.

Authors:  J Kohler; K L Dorso; K Young; G G Hammond; H Rosen; H Kropp; L L Silver
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens.

Authors:  G Jacoby; P Han; J Tran
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Distribution of the cfiA gene among Bacteroides fragilis strains in Japan and relatedness of cfiA to imipenem resistance.

Authors:  K Yamazoe; N Kato; H Kato; K Tanaka; Y Katagiri; K Watanabe
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  The bacteriology of gangrenous and perforated appendicitis--revisited.

Authors:  R S Bennion; E J Baron; J E Thompson; J Downes; P Summanen; D A Talan; S M Finegold
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

Review 6.  Antimicrobial resistance in anaerobes.

Authors:  B A Rasmussen; K Bush; F P Tally
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

7.  Mechanisms responsible for reduced susceptibility to imipenem in Bacteroides fragilis.

Authors:  R Edwards; D Greenwood
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

8.  Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study.

Authors:  K Bandoh; K Ueno; K Watanabe; N Kato
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

9.  In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).

Authors:  C J Gill; J J Jackson; L S Gerckens; B A Pelak; R K Thompson; J G Sundelof; H Kropp; H Rosen
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Sutterella wadsworthensis gen. nov., sp. nov., bile-resistant microaerophilic Campylobacter gracilis-like clinical isolates.

Authors:  H M Wexler; D Reeves; P H Summanen; E Molitoris; M McTeague; J Duncan; K H Wilson; S M Finegold
Journal:  Int J Syst Bacteriol       Date:  1996-01
  10 in total
  7 in total

1.  In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.

Authors:  Dianne B Hoellman; Linda M Kelly; Kim Credito; Lauren Anthony; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 2.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.

Authors:  C Betriu; A Sánchez; M L Palau; M Gómez; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 4.  Ertapenem: a review of its use in the treatment of bacterial infections.

Authors:  Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 6.  Ertapenem: a review of its use in the management of bacterial infections.

Authors:  Monique Curran; Dene Simpson; Caroline Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Descending necrotizing mediastinitis associated with Lactobacillus plantarum.

Authors:  Takahito Nei; Shunta Inai; Iwao Mikami; Akira Sato; Junichi Okamoto; Kazuhiko Yokoshima; Munenaga Nakamizo; Shuji Haraguchi; Kazunari Sonobe; Ryoichi Saito
Journal:  BMC Infect Dis       Date:  2013-08-29       Impact factor: 3.090
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.